Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial

Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial

Item

http://www.wikidata.org/entity/Q35885190

Q35885190

about

Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial

Item

http://www.wikidata.org/entity/Q35885190

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Tipranavir/Ritonavir (500/200 ...... ltinational, Multicenter Trial

@ast

Tipranavir/Ritonavir (500/200 ...... ltinational, Multicenter Trial

@en

type

Item

label

Tipranavir/Ritonavir (500/200 ...... ltinational, Multicenter Trial

@ast

Tipranavir/Ritonavir (500/200 ...... ltinational, Multicenter Trial

@en

prefLabel

Tipranavir/Ritonavir (500/200 ...... ltinational, Multicenter Trial

@ast

Tipranavir/Ritonavir (500/200 ...... ltinational, Multicenter Trial

@en

P1476

Tipranavir/Ritonavir (500/200 ...... ltinational, Multicenter Trial

@en

P2093

Damien V Cordery

http://www.w3.org/2001/XMLSchema#string

David A Cooper

http://www.w3.org/2001/XMLSchema#string

Frank Bergmann

http://www.w3.org/2001/XMLSchema#string

Joseph Scherer

http://www.w3.org/2001/XMLSchema#string

José L de Andrade Neto

http://www.w3.org/2001/XMLSchema#string

Keikawus Arastéh

http://www.w3.org/2001/XMLSchema#string

Patrick Robinson

http://www.w3.org/2001/XMLSchema#string

Ricardo L Chaves

http://www.w3.org/2001/XMLSchema#string

Roberto Zajdenverg

http://www.w3.org/2001/XMLSchema#string

study team

http://www.w3.org/2001/XMLSchema#string

P2860

Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study

Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir

Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir.

Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor

Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug r

Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples.

Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies.

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study.

HIV drug resistance detected during low-level viraemia is associated with subsequent virologic failure

Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients.

P304

e0144917

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0144917

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Keikawus Arastéh

Kiat Ruxrungtham

P577

2016-01-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

289488967

http://www.w3.org/2001/XMLSchema#string

P698

26730818

http://www.w3.org/2001/XMLSchema#string

P921

multicenter trial

P932

4701182

http://www.w3.org/2001/XMLSchema#string

Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial

about

Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698

P921

P932